CLAIMS

1. ~~A method for treating a breast cancer in an individual comprising administering to the individual a combination therapy which comprises~~ Use of a composition comprising an antagonist of a Programmed Death 1 protein (PD-1) and eribulin or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of breast cancer in an individual.

2. The ~~method~~ use of claim 1, wherein the individual is a human.

3. The ~~method~~ use of claim 1 or 2, wherein the breast cancer is a solid tumor.

4. The ~~method~~ use of any one of claims 1 to 3, wherein the breast cancer is triple negative breast cancer.

5. The ~~method~~ use of any one of claims 1 to 4, wherein the breast cancer is metastatic.

6. The ~~method~~ use of any one of claims 1 to 5, wherein the PD-1 antagonist is pembrolizumab and the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

7. A medicament comprising an antagonist of a Programmed Death 1 protein (PD-1) for use in combination with eribulin or a pharmaceutically acceptable salt thereof for treating a breast cancer in an individual.

8. A medicament comprising eribulin or a pharmaceutically acceptable salt thereof for use in combination with an antagonist of a Programmed Death 1 protein (PD-1) for treating a breast cancer in an individual.

9. The medicament of claim 7 or 8, wherein the individual is a human.

10. The medicament of any one of claims 7 to 9, wherein the breast cancer is a solid tumor that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

11. The medicament of any one of claims 7 to 10, wherein the breast cancer is triple negative breast cancer.

12. The medicament of any one of claims 7 to 11, wherein the breast cancer is metastatic.

13. The medicament of any one of claims 7 to 12, wherein the PD-1 antagonist is pembrolizumab and the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

14. The medicament of claim 13, wherein pembrolizumab is formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5, and eribulin or a pharmaceutically acceptable salt thereof is formulated as a liquid medicament which comprises 0.5 mg/mL eribulin mesylate or a pharmaceutically acceptable salt thereof.

15. A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), the second container comprises at least one dose of a medicament comprising eribulin or a pharmaceutically acceptable salt thereof, and the package insert comprises instructions for treating an individual for a breast cancer using the medicaments.

16. The kit of claim 15, wherein the instructions state that the medicaments are intended for use in treating an individual having a breast cancer that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

17. The kit of claim 15 or 16, wherein the individual is a human.

18. The kit of any one of claims 15 to 17, wherein the PD-1 antagonist is pembrolizumab formulated as a liquid medicament which comprises 25 mg/ml pembrolizumab, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5 and the pharmaceutically acceptable salt of eribulin is eribulin mesylate formulated as a liquid medicament which comprises 0.5 mg/mL eribulin mesylate.

19. The kit of any one of claims 15 to 18, wherein the breast cancer is triple negative breast cancer.

20. The kit of any one of claims 15 to 19, wherein the breast cancer is metastatic.

21. ~~A method for treating a human individual diagnosed with breast cancer, comprising administering to the individual a combination therapy which comprises~~ Use of a composition comprising pembrolizumab and eribulin or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of breast cancer in an individual, wherein the eribulin or the pharmaceutically acceptable salt thereof is administered at a dose of 1.4 mg/m^2, 1.1 mg/m^2, or 0.7 mg/m^2 on days 1 and 8 of a 21-day cycle and pembrolizumab is administered at a dose of 200 mg Q3W.

22. A medicament comprising: